Plenary Session Abstracts and Discussant Presentations-tGLI1 is a Novel Targetable Transcription Factor that Promotes Resistance to CDK4/6 Inhibitors and Chemoradiation in Glioblastoma

tGLI1 is a Novel Targetable Transcription Factor that Promotes Resistance to CDK4/6 Inhibitors and Chemoradiation in Glioblastoma - Ankush Chandra, MD, MS

Back to course

Video Transcription

Video Summary

Dr. Ankush Chandra presented research on TGLI-1, a novel transcription factor in GBM that mediates resistance to CDK4-6 inhibitors and chemoradiation, revealing significant alterations in the CDK4-6 pathway in 70% of GBMs. The study identified ketoconazole as a specific inhibitor of TGLI-1, which, when combined with CDK4-6 inhibitors, enhances treatment efficacy and reduces GBM resistance. Future research will explore TGLI-1's role in chemoradiation resistance and tumor microenvironment. Dr. Konstantinos Agyepanis praised the work but raised questions about TGLI-1's impact on glioma stem cells and therapy effectiveness.

Keywords

TGLI-1

GBM

CDK4-6 inhibitors

ketoconazole

chemoradiation resistance